



RECEIVED

APR 25 2000

1651

TECH CENTER 1600/2990

Attorney Docket No. 3495.0111-11

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bernard DUJON et al.

Serial Number: 09/492,697

Filed: January 27, 2000

Group Art Unit: 1651

Examiner: Unassigned

For: NUCLEOTIDE SEQUENCE ENCODING
THE ENZYME I-SCEI AND THE USES THEREOF

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449 sheets. This Information Disclosure Statement is being filed within three months of the filing date of the application and before receipt of a first Action on the merits in the above- referenced application.

Copies of the listed documents were previously submitted by applicants or cited by the Examiner in prior applications, Serial Nos. 09/244,130, filed February 4, 1999; 09/119,024, filed July 20, 1998; 08/336,241, filed 11/7/94; 07/971,160, filed 11/5/92; and 07/879,689, filed 5/5/92, upon which applicants rely for the benefits provided in 35 U.S.C. § 120. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

RECEIVED

APR 25 2000

Ser. No.: 09/492,697

TECH CENTER 1600/2900


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER L.L.P.

By: 
Salvatore J. Arrigo
Reg. No. 46,063

Dated: April 24, 2000